Marek Ziobro

712 citations
46 papers · 457 · 1 hit paper · h-index 11

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Pancreatic and Hepatic Oncology Research
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Immunotherapy and Biomarkers 9
    • HER2/EGFR in Cancer Research 8
    • Cancer Treatment and Pharmacology 7
    • Cutaneous Melanoma Detection and Management 5
    • Melanoma and MAPK Pathways 7

Marek Ziobro

36 papers receiving 450 citations

Marek Ziobro's Hit Papers

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma 2021 · 183 citations
1830+1+3Years since publication50100150

Peers

Marek Ziobro
Comparison fields: 5 of 52
  • Oncology 277
  • Cancer Research 130
  • Pulmonary and Respiratory Medicine 267
  • Molecular Biology 196
  • Immunology 37
Replace Yasser Ged with:
Yasser Ged United States
Ryo Ariyasu Japan
Ki Sun Jung South Korea
Alfonso Illiano Italy
Chukwuemeka Ikpeazu United States
Depei Huang China
Cinzia Baldessari Italy
Martin Eduardo Richardet Argentina
Federico Castiglione Italy
Paloma Martín-Martorell Spain
Marek Ziobro relative to Yasser Ged United States Yasser Ged's profile →
Citations per field
00.5×1.5×
Yasser Ged · 1×
Citations per year

Countries citing papers authored by Marek Ziobro

Since Specialization
Citations

This map shows the geographic impact of Marek Ziobro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Ziobro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Ziobro more than expected).

Fields of papers citing papers by Marek Ziobro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Ziobro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Ziobro. The network helps show where Marek Ziobro may publish in the future.

Co-authors

The 25 scholars most cited alongside Marek Ziobro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marek Ziobro Line = papers co-authored together Marek Ziobro links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
Hit paper breakdown →
2021183
2 201941
3 201925
4 201924
5 201217
6 201916
7 202015
8 201912
9
Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer.
201711
10 202211
11 201811
12 201210
13 20118
14 20208
15 20226
16 20226
17 20225
18
Effects of palliative treatment with temozolomide in patients with high-grade gliomas.
20085
19 20215
20 20225

About Marek Ziobro

Marek Ziobro is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 46 papers that have together received 457 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (10 papers), Cancer Immunotherapy and Biomarkers (9 papers), HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (7 papers), Melanoma and MAPK Pathways (7 papers), Renal cell carcinoma treatment (6 papers), Breast Lesions and Carcinomas (6 papers) and Cutaneous Melanoma Detection and Management (5 papers). The work is most often cited by research in Oncology (277 citations), Cancer Research (130 citations), Pulmonary and Respiratory Medicine (267 citations), Molecular Biology (196 citations) and Immunology (37 citations). Marek Ziobro has collaborated with scholars based in Poland, Hungary and United States. Frequent co-authors include Rustem Gafanov, Piotr Tomczak, David F. McDermott, Paweł Wiechno, Michael B. Atkins, B. Yа. Alekseev, В. Б. Матвеев, Frede Donskov, Rodolfo F. Perini and Jae‐Lyun Lee. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancers, Melanoma Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact